ten23 health® and SHL Medical announce a strategic partnership agreement for integrated services
ten23 health®, a leading Swiss Contract Development and Manufacturing Organization (CDMO) for sterile drugs, and SHL Medical, a world-leading provider of drug delivery devices, today announced their strategic partnership to provide a streamlined offering for pharmaceutical and biotech companies that require sterile drug-device combination products.
The partnership will allow SHL Medical to recommend and to integrate seamlessly with ten23 health for drug development and fill & finish, final assembly and final product testing of SHL autoinjectors to customers seeking such CDMO services.
ten23’s end-to-end offering includes formulation and process development, GMP fill and finish of syringes and cartridges, final assembly of autoinjectors and needle-safety devices, product testing and QC. The integration of ten23’s expertise and capabilities with SHL Medical’s autoinjector device technology will enhance the customer experience by guiding them through every step of the journey, from initial drug development to the successful commercialization of specific drug/device combination products.
”We are excited to partner with SHL, broadening our portfolio of device partnerships to deliver integrated patient-centric drug delivery solutions to pharmaceutical companies, tailored for their product needs,” said Prof. Dr. Hanns-Christian Mahler, Chief Enablement Officer of ten23 health. “The combination of strengths in this strategic partnership allows us to offer de-risked services and innovative and reliable drug delivery devices with clear patient focus.”
The collaboration will enable pharmaceutical companies to streamline their drug development processes and bring new therapies to market more efficiently by offering end-to-end solutions from drug formulation to final assembly of SHL Medical’s flagship platforms, Molly® 1.0 mL and 2.25 mL. The partnership between ten23 health and SHL Medical also underscores their commitment to driving innovation in drug delivery and enabling greater independence for patients.
“We are pleased to collaborate with ten23 health to complement our drug delivery offering with right-sized customer-focused solutions for small to medium assembly volumes,” said Ulrich Faessler, CEO of SHL. “By working together, we can leverage our combined capabilities to deliver innovative and patient-centric drug delivery solutions that address the evolving needs of the pharmaceutical industry.”
About ten23 health®
ten23 health®, located in Basel and Visp, Switzerland, is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups: we develop, manufacture, and test modern medicines. At our two sites in Basel and Visp, Switzerland, we support our clients in developing, manufacturing, and testing differentiated, stable, usable, and safe injectable treatment options for patients.
ten23 health combines the latest scientific findings with proven and tested world-class industry and regulatory expertise to forge new paths to support our clients. We provide innovative services in a fair and sustainable manner, respecting people’s health and the future of our planet. ten23 health is solidly financed through the long-term commitment of 3i Group, an internationally reputable equity partner.
About ten23’s company name
The numeric value for the number of molecules in a sample of one mol is called Avogadro constant and equals 6.022 * 10 23. Gram quantities of material contain the incredible number of 10 23 atoms, which was an important discovery to understand the composition of matter: The world is built from small units, and not a homogeneous mass.
For additional information, visit www.ten23.health
Media contact: Mara Willa, mara.willa@ten23.health ; +41 79 489 39 05
